Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam for sedation during AVF balloon dilatation in uraemic patients
ChiCTR2500115527Phase 4Not yet recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of remimazolam in end-stage kidney disease (ESKD) (2 arms), sponsored by Sir Run-Run Shaw Hospital. Primary endpoint: Patient Satisfaction Rating. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
remimazolam
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on ChiCTR2500115527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500115527.